Randomized multicenter 2 x 2-factorial design study of chemo/endocrine therapy in operable, node-positive breast cancer (protocol 2).
Scheurlen
H
H
Institut für Medizinische Biometrie und Informatik, Universität Heidelberg, FRG.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005069:Evaluation Studies as Topic; D005472:Fluorouracil / Q000008:administration & dosage; D005860:Germany, West; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008408:Mastectomy; D008727:Methotrexate / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D010819:Physician's Role; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D013629:Tamoxifen / Q000627:therapeutic use*
D013629:Tamoxifen; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate